BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22382009)

  • 1. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
    Saylor PJ; Escudier B; Michaelson MD
    Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to angiogenesis inhibitors in renal cell carcinoma.
    Tamaskar I; Dhillon J; Pili R
    Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.
    Massari F; Ciccarese C; Santoni M; Lopez-Beltran A; Scarpelli M; Montironi R; Cheng L
    Expert Rev Anticancer Ther; 2015; 15(12):1367-9. PubMed ID: 26568023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
    Sonpavde G; Willey CD; Sudarshan S
    Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
    Ebbinghaus SW; Gordon MS
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.
    Schirner M; Hoffmann J; Menrad A; Schneider MR
    Clin Cancer Res; 1998 May; 4(5):1331-6. PubMed ID: 9607594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
    Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
    BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antiangiogenic therapies for renal cell cancer.
    Gordon MS
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
    Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
    Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies.
    Moccia F; Dragoni S; Poletto V; Rosti V; Tanzi F; Ganini C; Porta C
    Anticancer Agents Med Chem; 2014 Feb; 14(2):296-312. PubMed ID: 23869775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.
    Tran TA; Leong HS; Pavia-Jimenez A; Fedyshyn S; Yang J; Kucejova B; Sivanand S; Spence P; Xie XJ; Peña-Llopis S; Power N; Brugarolas J
    Mol Cell Biol; 2016 Jul; 36(13):1836-55. PubMed ID: 27141054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.